menu

OUR VISION

Our company is guided by the following "BTB" goals.

Bench To Bedside：We develop novel therapeutic drugs by translating the ideas and discoveries in basic research.

Bedside To Bench：We perform R&D with the aim for tackling unmet medical needs.

Beyond Traditional Benchmark：We conduct drug development research based on evaluation metrics that differ from traditional benchmarks.

Borderless Translational Biology：We promote interdisciplinary collaboration across different hospital departments and academic fields.

Bundling Transdisciplinary Branches：We coordinate the launch of new drugs in clinical trials by working across various hospital departments and academic settings.

Breeding Therapeutic Breakthroughs：We perform R&D with the attitude of constantly delivering new knowledge in the world.

 

 

NEWS

  • 2021-12-22

    We are delighted to announce our participation in the upcoming event as a venture corporation coming from academia.

    ＜Event＞
    The Third Kyoto University Life Science Showcase@San Diego 2022

    ＜Event date and time＞
    7:00 a.m.–10:00 a.m. (Japan time) March 2nd, 2022 (Wed)

  • 2021-12-22

    The 5th recorded video of the web seminar "Proposals from Kyoto University," which was held on December 14th, 2021 (Tuesday), co-sponsored by Kyoto University and Kyodai Collaborative (*), has been released on the official YouTube channel.
    (*Kyodai Collaborative: A newly established NPO based in the US whose aim it is to connect Kyoto University alumni and supporters)

    ●Kyoto University YouTube video
    ●Kyodai Collaborative YouTube video

    ＜Theme＞
    "Let’s Change the World Starting From Small Things! An Original Method to Grow Startups Coming from Kyoto University"
    We will discuss the original method for building startups from Kyoto University, together with ways in which the newly established, US-based NPO Kyodai Collaborative can be involved.

    ＜Presenters＞
    ・Masatoshi Hagiwara Professor, Graduate School of Medicine, Kyoto University/ Director, iSAL, Kyoto University
    ・Devang Thakor, Representative, Anioplex, LLC/Deputy Representative, Intellectual Property, Turn Biotechnologies, Inc./ Chairman, Kyodai Collaborative

    Moderator: Yuki Sako, Lawyer (K & L Gates Law Office)/Director, Kyodai Collaborative Director (graduate of Kyoto University )

  • 2021-07-02
    We received the BioLabs Award at the HVC KYOTO (Healthcare Venture Conference KYOTO), one of the largest English-language pitch events in Japan in the healthcare field.
  • 2021-04-15

    We received an investment from Kyoto University Innovation Capital Co., Ltd. and a press release was made. It was also published in the Nihon Keizai Shimbun (April 6th).

    Kyoto University based drug discovery startup BTB Drug Development Research Center (Kyoto City) has raised \100 million from venture capital firms associated with Kyoto University. This will be used for drug research and development. BTB are developing painkillers that can reduce postoperative pain, and will simultaneously begin clinical trials within Japan and overseas in FY2022.
  • 2021-03-10
    The another project has been selected for drug discovery support promotion project at 2021 - Practical application support project for the drugs of rare disease by the Japan Agency for Medical Development(AMED). Title: Development of a new drug for the splicing mutant genetic patients.
  • 2021-01-07
    The project has been selected for the 5th Call for Applications (ViCLE Practical Application Development
    Type) for the Creation of Innovative Core for Medical Research and Development (CiCLE) by the Japan
    Agency for Medical Development (AMED). Title: Development of ENDOPIN, a novel non-NSAIDS/non-
    opioid painkiller
  • 2020-09-15
    The website of BTB Drug Development Research Center has been updated.